Zevra Therapeutics, Inc. (ZVRA) has disclosed a new risk, in the Accounting & Financial Operations category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zevra Therapeutics, Inc. has recently recognized an impairment charge of $58.7 million related to its definite-lived intangible assets for the quarter ending June 30, 2025. This financial adjustment highlights the potential risk of further impairments, which could adversely impact the company’s operating results. The evaluation of potential impairment involves significant judgment, considering factors such as changes in asset utilization, economic trends, and performance metrics. Future impairments could arise from these variables, posing a risk to the company’s financial stability.
The average ZVRA stock price target is $22.29, implying 136.37% upside potential.
To learn more about Zevra Therapeutics, Inc.’s risk factors, click here.